Dr Sara Lonardi speaks to ecancer about the results of the phase II PANDA study, which she presented at the ASCO 2020 virtual meeting and assessed the combination of first-line FOLFOX plus panitumumab versus 5FU and panitumumab in elderly patients with RAS-BRAF wild-type (WT) metastatic colorectal cancer.
She states that the standard recommended treatment for these patients is FOLFOX/LV monotherapy, but there have been no randomised trials investigating the addition of anti-EGFR monoclonal antibody.
Dr Lonardi outlines the design and results of the trial, which met its primary endpoint in both treatment arms.
However, she mentions the group are awaiting mature overall survival data and is conducting further translational analyses using tissue and blood samples.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.